Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7457.09 | 0.0087 | -0.8694 | 1.7392 | |
| HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7457.09 | 0.0085 | -0.8714 | 1.7392 | |
| HCC202 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7458.091 | 0.9557 | 0.8419 | 0.5499 | |
| HCC202 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7458.091 | 1.0124 | 1.0452 | 0.5499 | |
| HCC202 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7458.091 | 0.9821 | 0.9354 | 0.5499 | |
| HCC202 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7458.091 | 0.9515 | 0.8271 | 0.5499 | |
| HCC202 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7458.091 | 0.9820 | 0.9349 | 0.5499 | |
| HCC202 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7458.091 | 0.9099 | 0.6845 | 0.5499 | |
| HCC202 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7458.091 | 0.6704 | -0.0334 | 0.5499 | |
| HCC202 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7458.091 | 0.0201 | -0.9984 | 0.5499 | |
| HCC202 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7458.091 | 0.0086 | -0.9997 | 0.5499 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7462.092 | 0.9723 | 0.8747 | 0.4336 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7462.092 | 0.9868 | 0.9396 | 0.4336 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7462.092 | 0.9855 | 0.9337 | 0.4336 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7462.092 | 0.7872 | 0.1518 | 0.4336 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7462.092 | 0.9872 | 0.9415 | 0.4336 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7462.092 | 0.9314 | 0.6978 | 0.4336 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7462.092 | 0.7899 | 0.1610 | 0.4336 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7462.092 | 0.0118 | -0.9999 | 0.4336 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7462.092 | 0.0068 | -1.0000 | 0.4336 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7463.09 | 0.9608 | 0.8593 | 0.5483 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7463.09 | 0.9336 | 0.7645 | 0.5483 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7463.09 | 0.9674 | 0.8827 | 0.5483 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7463.09 | 0.9536 | 0.8339 | 0.5483 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7463.09 | 0.9614 | 0.8614 | 0.5483 |